Evidence map›Paper›PMID 31079079›Full record

ArticleBMJ open2019

Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer-the 5C study: a study protocol for a randomised controlled phase III trial.

Martine T E Puts, Tina Hsu, Caroline Mariano, Johanne Monette, Sarah Brennenstuhl, Eric Pitters, Jack Ray, Doreen Wan-Chow-Wah, Natascha Kozlowski, Monika Krzyzanowska and 18 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03154671 (Clinical and Cost-effectiveness of a Comprehensive Geriatric Assessment and Management for Canadian Elders With Cancer), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03154671 nacompletednot on this map

Clinical and Cost-effectiveness of a Comprehensive Geriatric Assessment and Management for Canadian Elders With Cancer: the 5C Study

TypeinterventionalSponsorUniversity of TorontoRan2018 to 2021Enrolled351ConditionsCancerArmsGeriatric assessment and management
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 13 institutions in 1 country.

Martine T E PutsLawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada.
Tina HsuDivision of Medical Oncology, The Ottawa Hospital, Ottawa, Ontario, Canada.
Caroline MarianoDepartment of Medical Oncology, The Royal Columbian Hospital, New Westminster, British Columbia, Canada.
Johanne MonetteDivision of Geriatric Medicine, The Jewish General Hospital, Montreal, Quebec, Canada.
Sarah BrennenstuhlLawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada.
Eric PittersOlder adult representative, Oshawa, Ontario, Canada.
Jack RayOlder adult representative, Calgary, Alberta.
Doreen Wan-Chow-WahDivision of Geriatric Medicine, The Jewish General Hospital, Montreal, Quebec, Canada.
Natascha KozlowskiDepartment of Medical Oncology, R.S. McLaughlin Durham Regional Cancer Centre, Lakeridge Health, Oshawa, Ontario, Canada.
Monika KrzyzanowskaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Eitan AmirDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Christine ElserDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Raymond JangDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Anca PricaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Murray KrahnToronto Health Economics and Technology Assessment Collaborative, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
Francois BelandPublic Health School, University of Montreal, Montreal, Quebec, Canada.
Simon BergmanDepartment of Surgery, Jewish General Hospital, Montreal, Quebec, Canada.
Rama KoneruDepartment of Medical Oncology, R.S. McLaughlin Durham Regional Cancer Centre, Lakeridge Health, Oshawa, Ontario, Canada.
Manon LemondeFaculty of Health Sciences, University of Ontario Institute of Technology, Oshawa, Ontario, Canada.
Ewa SzumacherDepartment of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Joan ZidulkaDepartment of Oncology, St. Mary's Hospital, Montreal, Quebec, Canada.
Shek FungDepartment of Oncology, St. Mary's Hospital, Montreal, Quebec, Canada.
Anson LiDepartment of Geriatric Medicine, Royal Columbian Hospital, New Westminster, British Columbia, Canada.
Urban EmmeneggerDepartment of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Rajin MehtaDivision of Geriatric Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Kendra FlemmingLawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada.
Henriette BreunisDepartment of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Shabbir M H AlibhaiDepartment of Medicine and Institute of Health Policy, Management, and Evaluation, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Princess Margaret Cancer Centre · CAUniversity of Toronto · CAJewish General Hospital · CAUniversity Health Network · CAHealth Sciences Centre · CARoyal Columbian Hospital · CASt Mary's Hospital · CALakeridge Health · CAOttawa Hospital · CARegional Municipality of Durham · CASunnybrook Health Science Centre · CAUniversité de Montréal · CAUniversity of Ontario Institute of Technology · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGeriatric assessment and management is recommended for older adults with cancer referred for chemotherapy but no randomised controlled trial has been completed of this intervention in the oncology setting. TRIAL

designA two-group parallel single blind multi-centre randomised trial with a companion trial-based economic evaluation from both payer and societal perspectives with process evaluation.

participantsA total of 350 participants aged 70+, diagnosed with a solid tumour, lymphoma or myeloma, referred for first/second line chemotherapy, who speak English/French, have an Eastern Collaborative Oncology Group Performance Status 0-2 will be recruited. All participants will be followed for 12 months.

interventionGeriatric assessment and management for 6 months. The control group will receive usual oncologic care. All participants will receive a monthly healthy ageing booklet for 6 months.

objectiveTo study the clinical and cost-effectiveness of geriatric assessment and management in optimising outcomes compared with usual oncology care. RANDOMISATION: Participants will be allocated to one of the two arms in a 1:1 ratio. The randomisation will be stratified by centre and treatment intent (palliative vs other). OUTCOME: Quality of life. SECONDARY OUTCOMES: (1) Cost-effectiveness, (2) functional status, (3) number of geriatric issues successfully addressed, (4) grades3-5 treatment toxicity, (5) healthcare use, (6) satisfaction, (7) cancer treatment plan modification and (8) overall survival. PLANNED ANALYSIS: For the primary outcome we will use a pattern mixture model using an intent-to-treat approach (at 3, 6 and12 months). We will conduct a cost-utility analysis alongside this clinical trial. For secondary outcomes 2-4, we will use a variety of methods. ETHICS AND DISSEMINATION: Our study has been approved by all required REBs. We will disseminate our findings to stakeholders locally, nationally and internationally and by publishing the findings. TRIAL REGISTRATION NUMBER: NCT03154671.

Indexed as

Geriatric AssessmentNeoplasmsAgedAntineoplastic AgentsCanadaClinical Trials, Phase III as TopicCost-Benefit AnalysisHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicSingle-Blind MethodTreatment OutcomeAntineoplastic Agentscomprehensive geriatric assessmentcost-effectiveness analysesfrail elderlygeriatric oncologyrandomized controlled trial

Identifiers

PMID31079079
PMCPMC6530407
OpenAlexW2943922412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.